Nikola Sprigg, Principal Investigator of the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial (ISRCTN93732214), which previously reported that tranexamic acid does not improve outcome in adults with stroke due to intracerebral haemorrhage despite reducing haematoma expansion, shares results and insights from one-year follow up data.
Content produced in Milan, Italy and shared with kind authorisation of the European Stroke Organisation (ESO) and the European Stroke Organisation Conference (ESOC 2019).
Share this Video
Related Videos In Stroke
Update on the European Stroke Organisation Conference (ESOC) 2023: Peter Kelly
The European Stroke Organisation Conference (ESOC) 2023 will take place 24-26 May 2023 in Munich, Germany. The conference will include sessions, plenary lectures, and symposia, covering a wide range of topics related to stroke, including acute management, rehabilitation, imaging, epidemiology, and public health. Prof. Peter Kelly (President, European Stroke Organisation, Dublin, Ireland) joins touchNEUROLOGY to […]
Hariklia Proios, Stroke Alliance for Europe (SAFE): Presidential Update
The Stroke Alliance for Europe (SAFE) is a non-profit-making organisation that represents a range of patient groups from across Europe. Their mutual goal is to drive stroke prevention up the European political agenda and prevent the incidence of stroke through education. touchNEUROLOGY caught up with the SAFE President, Prof. Hariklia (Harriet) Proios, to discuss the […]
Martin Bretzner, ESOC 2022: Brain-age biomarkers to predict post-stroke recovery
Brain-age biomarkers can be used to predict post-stroke recovery. Dr Martin Bretzner (Lille Neuroscience & Cognition Research Centre, Lille University Hospital, Lille, France) discusses the results of a study using radiomics, an emerging image-quantifying technology to assess ‘brain-age’ biomarkers. The study investigates how relative brain age, rather than chronological age, can enhance stroke surveillance and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!